Phase II Study of ENMD-2076 in Chinese Patients With Ovarian Clear Cell Carcinomas

Trial Profile

Phase II Study of ENMD-2076 in Chinese Patients With Ovarian Clear Cell Carcinomas

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs ENMD 2076 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2015 New trial record
    • 30 Mar 2015 According to CASI Pharmaceuticals media release,China Food and Drug Administration (CFDA) has approved the application to conduct a Phase 2 clinical trial in ovarian clear cell carcinoma patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top